The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds

WLY Cover Image

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. That said, here is one profitable company that leverages its financial strength to beat the competition and two that may face some trouble.

Two Stocks to Sell:

Wiley (WLY)

Trailing 12-Month GAAP Operating Margin: 14.3%

With roots dating back to 1807 when Charles Wiley opened a small printing shop in Manhattan, John Wiley & Sons (NYSE: WLY) is a global academic publisher that provides scientific journals, books, digital courseware, and knowledge solutions for researchers, students, and professionals.

Why Are We Out on WLY?

  1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 1.9% annually over the last five years
  2. Free cash flow margin dropped by 7.3 percentage points over the last five years, implying the company became more capital intensive as competition picked up
  3. Underwhelming 10.8% return on capital reflects management’s difficulties in finding profitable growth opportunities

Wiley’s stock price of $42.25 implies a valuation ratio of 1.4x trailing 12-month price-to-sales. Read our free research report to see why you should think twice about including WLY in your portfolio.

WEX (WEX)

Trailing 12-Month GAAP Operating Margin: 25.7%

Originally founded in 1983 as Wright Express to serve the fleet card market, WEX (NYSE: WEX) provides payment processing and business solutions across fleet management, employee benefits, and corporate payments sectors.

Why Do We Think Twice About WEX?

  1. Muted 2.6% annual revenue growth over the last two years shows its demand lagged behind its financials peers
  2. Earnings growth over the last two years fell short of the peer group average as its EPS only increased by 5.2% annually
  3. Underwhelming 10% return on equity reflects management’s difficulties in finding profitable growth opportunities

WEX is trading at $171.96 per share, or 10.8x forward P/E. Check out our free in-depth research report to learn more about why WEX doesn’t pass our bar.

One Stock to Watch:

ResMed (RMD)

Trailing 12-Month GAAP Operating Margin: 32.7%

Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE: RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.

Why Does RMD Stand Out?

  1. Steady constant currency growth over the past two years shows the company can pursue its global ambitions, even in uncertain economic times
  2. Additional sales over the last five years increased its profitability as the 14.9% annual growth in its earnings per share outpaced its revenue
  3. Free cash flow margin jumped by 12.5 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends

At $275 per share, ResMed trades at 26.3x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Stocks We Like Even More

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.